Clinical Trial

. 2024 Jun 20;137(12):1480-1482.

doi: 10.1097/CM9.0000000000003071. Epub 2024 Apr 1.

Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: A multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial

Xue Chen¹, Xiuping Han², Bo Cheng³, Hui Li⁴, Lingling Liu⁵, Songmei Geng⁶, Linfeng Li⁷, Jie Li⁸, Qing Guo⁹, Guoyi Zhang¹⁰, Hong Fang¹¹, Jianzhong Zhang¹

Affiliations

¹ Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
² Department of Dermatology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110055, China.
³ Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350004, China.
⁴ Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
⁵ Department of Dermatology, Peking University First Hospital, Beijing 100034, China.
⁶ Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xi'an, Shaanxi 710006, China.
⁷ Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
⁸ Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
⁹ Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, China.
¹⁰ Department of Dermatology, Hospital for Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, Jiangsu 210042, China.
¹¹ Department of Dermatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China.

PMID: 38557589
PMCID: PMC11188862
DOI: 10.1097/CM9.0000000000003071

Clinical Trial

Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: A multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial

Xue Chen et al. Chin Med J (Engl). 2024.

. 2024 Jun 20;137(12):1480-1482.

doi: 10.1097/CM9.0000000000003071. Epub 2024 Apr 1.

Authors

Xue Chen¹, Xiuping Han², Bo Cheng³, Hui Li⁴, Lingling Liu⁵, Songmei Geng⁶, Linfeng Li⁷, Jie Li⁸, Qing Guo⁹, Guoyi Zhang¹⁰, Hong Fang¹¹, Jianzhong Zhang¹

Affiliations

¹ Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
² Department of Dermatology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110055, China.
³ Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350004, China.
⁴ Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
⁵ Department of Dermatology, Peking University First Hospital, Beijing 100034, China.
⁶ Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xi'an, Shaanxi 710006, China.
⁷ Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
⁸ Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
⁹ Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, China.
¹⁰ Department of Dermatology, Hospital for Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, Jiangsu 210042, China.
¹¹ Department of Dermatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China.

PMID: 38557589
PMCID: PMC11188862
DOI: 10.1097/CM9.0000000000003071

No abstract available

PubMed Disclaimer

Conflict of interest statement

None.

Cited by

Bilastine Reimagined: A Comprehensive Exploration of Pruritus Management With a Novel Antihistamine.
Mahajan BB, Banodkar P, Bhardwaj G, Gokhale N, Nischal KC, Ahmed SKS, Sharma A, Mayabhate M, Jaju TA. Mahajan BB, et al. Cureus. 2024 Oct 10;16(10):e71232. doi: 10.7759/cureus.71232. eCollection 2024 Oct. Cureus. 2024. PMID: 39525204 Free PMC article. Review.
Data mining in FAERS: association of newer-generation H1-antihistamines with nervous system disorders.
Hu W, Li H, Zeng L, Gan J, Feng C, Chen L, Zhang L. Hu W, et al. BMC Pharmacol Toxicol. 2024 Dec 18;25(1):95. doi: 10.1186/s40360-024-00822-x. BMC Pharmacol Toxicol. 2024. PMID: 39696617 Free PMC article.

References

1. Li J Mao D Liu S Liu P Tian J Xue C, et al. . Epidemiology of urticaria in China: a population-based study. Chin Med J 2022;135:1369-1375. doi: 10.1097/CM9.0000000000002172. - PMC - PubMed
1. Vanitha M, Sowmini K, Santha Sheela Kumari K, Reedy RN. Efficacy of oral bilastine in comparison with levocetirizine in allergic rhinitis – A randomised clinical study. J Clin Diag Res 2021;15:FC01-FC04. doi: 10.7860/JCDR/2021/48303.15183.
1. Wang XY, Lim-Jurado M, Prepageran N, Tantilipikorn P, Wang de Y. Treatment of allergic rhinitis and urticaria: A review of the newest antihistamine drug bilastine. Ther Clin Risk Manag 2016;12:585-597. doi: 10.2147/TCRM.S105189. - PMC - PubMed
1. Podder I, Das A, Ghosh S, Biswas D, Sengupta S, Chowdhury SN. Effectiveness, safety, and tolerability of bilastine 20 mg vs. levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial. Dermatol Ther 2020;33:e13946. doi: 10.1111/dth.13946. - PubMed
1. Xue X Wang Q Yang X Tu H Deng Z Kong D, et al. . Effect of bilastine on chronic urticaria: A systematic review and meta-analysis. Int Arch Allergy Immunol 2023;184:176-185. doi: 10.1159/000527181. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: A multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial

Affiliations

Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: A multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources